Latest Breaking News On - Veeva vault clinical - Page 3 : comparemela.com

Veeva (NYSE: VEEV) recently reported its first quarter results that continued to surpass all market expectations. The market was pleased with its performance, and the stock rallied 7% in the after-hours trading session. Veeva's Financials Veeva's Q1 revenues grew 4% to $526.3 million, ahead of the Street's forecast by 2.1%. On an adjusted basis, EPS was $0.91, surpassing the Street's estimates of $0.79. By segment, revenues from subscription services grew 3% to $414.5 million. Professional services revenues grew 9% to $111.78 million. For the second quarter, Veeva forecast revenues of $580-$582 million and an adjusted EPS of $1.12-$1.13. The market was looking for revenues of $577.71 million and an EPS of $1.05. Veeva expects to end the current year with revenues of $2.36-$2.37 billion and an EPS of $4.59. The market was looking for revenues of $2.35 billion and an adjusted EPS of $4.32. Veeva's Product Growth Recently, Veeva announced its partnership with UCB

Veeva development cloudLotus clinical researchVeeva vault clinicalVault clinical suiteTechnology stocks